Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kunitz-type serine protease inhibitor toxins are a prominent family of small, disulfide-rich proteins found extensively in the venoms of snakes, spiders, and other venomous organisms. These toxins are characterized by a conserved structural motif known as the Kunitz domain, which typically contains three highly stable disulfide bonds. Their primary biological mechanism involves the potent, competitive inhibition of host serine proteases, such as plasmin, trypsin, and kallikrein, which can lead to severe disruptions in blood coagulation and fibrinolysis (Ranasinghe & McManus, 2013). Additionally, some members of this family, such as dendrotoxins, have evolved to target voltage-gated potassium channels, acting as potent neurotoxins that trigger neurotransmitter release and convulsions (Wan et al., 2013). From a therapeutic perspective, these molecules have served as templates for drug development, most notably aprotinin, which was used clinically to reduce perioperative bleeding. However, their use as drugs or their presence in venom poses significant safety challenges, including the risk of life-threatening anaphylaxis and potential nephrotoxicity (UniProt KB). Modern research continues to explore these inhibitors as scaffolds for highly specific therapeutic agents targeting cancer and inflammatory pathways.
Competitive inhibition of serine proteases via a non-cleavable bait loop that binds the active site; physical blockade of voltage-gated potassium channels.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kunitz-type serine protease inhibitor (KPI).